HK-001 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 2 | Amyotrophic lateral sclerosis | 1 |
2. Amyotrophic lateral sclerosis
Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03651349 (ClinicalTrials.gov) | February 1, 2021 | 26/8/2018 | To Determine the Maximum Tolerated Dose (MTD) of HK-001 in Healthy Volunteers | A Phase I Study to Determine the Maximum Tolerated Dose (MTD) of HK-001 and to Evaluate Its Pharmacokinetic Profile in Healthy Volunteers | Amyotrophic Lateral Sclerosis | Drug: HK-001;Drug: Placebo control | Everfront Biotech Co., Ltd. | NULL | Active, not recruiting | 20 Years | N/A | All | 56 | Phase 1 | Taiwan |